Quick Answer
VERTEX PHARMACEUTICALS INC / MA reported Revenue (ASC 606) of $12.00 billion for fiscal year 2025.
VERTEX PHARMACEUTICALS INC / MA Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $12.00B | +8.9% |
| 2024 | $11.02B | +11.7% |
| 2023 | $9.87B | +10.5% |
| 2022 | $8.93B | +17.9% |
| 2021 | $7.57B | +22.1% |
| 2020 | $6.21B | +49.1% |
| 2019 | $4.16B | +36.6% |
| 2018 | $3.05B | +22.5% |
| 2017 | $2.49B | +46.2% |
| 2016 | $1.70B | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.08B | +11.0% | +3.8% |
| June 30, 2025 | $2.96B | +12.1% | +7.0% |
| March 31, 2025 | $2.77B | +3.0% | -0.1% |
| September 30, 2024 | $2.77B | +11.6% | +4.8% |
| June 30, 2024 | $2.65B | +6.1% | -1.7% |
| March 31, 2024 | $2.69B | +13.3% | +8.3% |
| September 30, 2023 | $2.48B | +6.4% | -0.4% |
| June 30, 2023 | $2.49B | +13.5% | +5.0% |
- VERTEX PHARMACEUTICALS INC / MA showed an increase of +8.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, VERTEX PHARMACEUTICALS INC / MA’s revenue (asc 606) has grown by 605.1% (from $1.70 billion to $12.00 billion).
- The most recent figure is from VERTEX PHARMACEUTICALS INC / MA’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: